You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
Under a contract with BARDA, First Light is developing a digital imaging-based diagnostics platform, as well as tests for anthrax and urinary tract infections.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.
The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.
The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.
The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.
Called Ion, the system combines low magnification, high-resolution imaging with a proprietary image analysis algorithm for rapid pathogen detection.
The grant will support the development of a high-throughput method to extract and test dried blood samples collected by patients at home.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
The Finnish company also announced that it has received CE-IVD marking for its Aiforia Clinical pathology image analysis platform.
The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test.
The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
The company raised $7.4 million in an extended Series B financing round and entered a partnership with BARDA valued at $7.6 million.
The company's Nanotrap technology uses hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.
Erada Technology Alliance said the Global Health Innovative Technology Fund grant facilitates production, testing, and validation trials for the rapid test for malaria.
For the first time ever, the center is funding the development of diagnostic systems — specifically for the development of three devices to detect the infection.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.